Is Trinity Biotech plc (TRIB) a Buy, Sell, or Hold?
NASDAQ : TRIB
Trinity Biotech plc
$0.335 USD
$0.0 (-0.15%)
- Volume
- 331.45K
- Average Volume
- 1.31M
- Market Capitalization
- $3.48M
- P/E Ratio
- -0.17
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $3.44
- Year Low
- $0.31
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.25
Company Overview
NASDAQ
John Gillard
Medical - Diagnostics & Research
Healthcare
TRIB
287
IE
USD
Liquidity Metrics
-1.92
0.25
0.12
0.04
0.00
Sales & Valuation
$43.78M
0.08
-0.09
-0.55
-0.34
Profitability
-$2
-$37.38M
-85.32%
-84.86%
68.09%
-35.59%
P/E Metrics
-0.17
0.00
0.00
Analyst Price Target & Rating
2/5
4 Analysts
%
Financial Health Scores
-2.67
3/9
-$105.31M
$105.16M
$177.15M
-$11.26M
Key Metrics (TTM)
$136.32M
3.11
-15.92
0.25
68.09%
-15.05%
-599.74%
-182.33%
-55 days
Company Executives
| Name | Title |
|---|---|
| John Gillard | President, Chief Executive Officer, Company Secretary & Director |
| Ronan O'Caoimh | Founder, Director & Executive Advisor |
| Paul Murphy | Interim Chief Financial Officer |
| Eibhlin Kelly | Chief Information Officer |
| Jacqueline O'Neill | Director of Operations |
| Gary Keating | Chief Technology Officer |
| Jerry Lydon | Head of North America Commercial Operations |
| James Walsh | Executive Director of Business Development & Executive Director |
Poll Results
No votes yet today — be the first to share your view!
About Trinity Biotech plc (NASDAQ:TRIB) Stock
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products c ... entered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
2026-07-02 08:30:00
- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech's CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows - Demonstrates practical value of Trinity Biotech's proprietary multi-sensor wearable biosensor technology beyond glucose-only CGM monitoring - Reinforces differentiation opportunity for CGM+ within the $15 billion1 global CGM market DUBLIN and WILSONVILLE, Ore., July 02, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced clinical study results demonstrating that its next-generation CGM+ wearable biosensor platform has successfully delivered a purpose-built capability to identify nocturnal compression-related false low glucose events, with its differentiated technology addressing a common limitation of conventional continuous glucose monitoring (CGM) systems.
2026-06-30 09:00:00
- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by 2033 1 DUBLIN and WILSONVILLE, Ore., June 30, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that Trinovium, its recently established subsidiary focused on high-performance liquid cooling solutions for AI data centers, has secured Silver Membership in the Open Compute Project (OCP), providing Trinovium with a platform to directly engage with one of the most influential global ecosystems shaping next-generation data center infrastructure.
Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville
2026-06-29 15:15:00
DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that it has formally provided notice of termination to YA II PN, LTD., an affiliate of financing partner Yorkville Advisors Global, in respect of its Standby Equity Purchase Agreement (the “SEPA”) for an equity line of credit facility.
2026-06-23 07:30:00
- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-performance computing environments
2026-06-16 09:10:00
– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets
Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations
2026-05-01 09:27:00
- Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces further operational progress in its Comprehensive Transformation Plan - Company publishes Q4 2025 financial results with revenue broadly in line with previously issued trading update & year-on-year gross margin percentage improvements DUBLIN, May 01, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ: TRIB) (“Trinity” or the “Company”), a commercial‑stage diagnostics and health technology company, today announced the appointment of Jerry Lydon as Head of North America Commercial Operations. Mr. Lydon's appointment represents a deliberate next step as the Company's core diagnostics business transitions from the execution phase of its Comprehensive Transformation Plan toward a sustained focus on building revenue momentum and, importantly, driving profitability from a more efficient and disciplined operating base.
Frequently Asked Questions
-
What is the current Trinity Biotech plc (TRIB) stock price?
-
Trinity Biotech plc(NASDAQ:TRIB) stock price is $0.335 in the last trading session. During the trading session, TRIB stock reached the peak price of $3.44 while $0.31 was the lowest point it dropped to. The percentage change in TRIB stock occurred in the recent session was --0.15% while the dollar amount for the price change in TRIB stock was -$0.0.
-
TRIB's industry and sector of operation?
-
The NASDAQ listed TRIB is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of TRIB?
-
John Gillard | President, Chief Executive Officer, Company Secretary & Director
Ronan O'Caoimh | Founder, Director & Executive Advisor
Paul Murphy | Interim Chief Financial Officer
Eibhlin Kelly | Chief Information Officer
Jacqueline O'Neill | Director of Operations -
How many employees does TRIB have?
-
Number of TRIB employees currently stands at 287. TRIB operates from IDA Business Park, Bray, WW A98 H5C8, IE.
-
Link for TRIB official website?
-
Official Website of TRIB is: https://www.trinitybiotech.com
-
How do I contact TRIB?
-
TRIB could be contacted at phone #353 1 276 9800 and can also be accessed through its website. TRIB operates from IDA Business Park, Bray, WW A98 H5C8, IE.
-
How many shares of TRIB are traded daily?
-
The average number of TRIB shares traded daily for last 3 months was 1.31M.
-
What is the market cap of TRIB currently?
-
The market value of TRIB currently stands at $3.48M with its latest stock price at $0.335